Prostate Cancer - Results from #340

Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status. September 4, 2024

Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System. September 4, 2024

Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. September 4, 2024

MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer. September 3, 2024

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). September 3, 2024

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Regi September 3, 2024

Clinical implementation of real time motion management for prostate SBRT: A radiation therapist's perspective. September 3, 2024

Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound. September 3, 2024

Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men. September 3, 2024

Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer. September 2, 2024

Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study. September 2, 2024

Immune effects of α and β radionuclides in metastatic prostate cancer. September 2, 2024

Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience. September 2, 2024

Diffusion MRI in prostate cancer with ultra-strong whole-body gradients. September 2, 2024

68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. September 2, 2024

Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. August 30, 2024

The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer. August 30, 2024

Prostate Cancer Early Detection in the European Union and UK. August 30, 2024

Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer. August 30, 2024

PARP inhibitors alone or in combination for prostate cancer. August 30, 2024

Page 18 of 1436